公开(公告)号：US11384148B2

公开(公告)日：2022-07-12

申请号：US16271086

申请日：2019-02-08

Applicant: UCB Biopharma SPRL

Inventor： Helene Margaret Finney ,  Alastair David Griffiths Lawson ,  Stevan Graham Shaw ,  Bryan John Smith ,  Kerry Louise Tyson ,  Lara Kevorkian ,  Christoph Meier ,  Kaushik Sarkar ,  Paul Alan Atherfold

IPC: A61K39/395 ,  A61K39/40 ,  C07K16/28 ,  G01N33/50 ,  G01N33/564 ,  G01N33/68 ,  A61K47/60 ,  A61K47/64 ,  C07K16/00 ,  A61K39/00

Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.

公开(公告)号：US20150232553A1

公开(公告)日：2015-08-20

申请号：US14585406

申请日：2014-12-30

Applicant: UCB BIOPHARMA SPRL

Inventor： Helene Margaret Finney ,  Terence Seward Baker ,  Alastair David Griffiths Lawson ,  Karen Margrete Miller ,  Marc Roger de Ryck ,  Christian Gilbert J. Wolff

IPC: C07K16/28

CPC classification number: C07K16/28 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76

Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

Abstract translation: 结合后的Nav1.7结合实体功能性地修饰离子通道的活性，特别是抗Nav1.7抗体或其结合片段，包含所述抗体的药物组合物，使用抗体及其组合物在治疗中 ，例如在疼痛的治疗/调节中以及产生和制备所述抗体的方法。

公开(公告)号：US20150203571A1

公开(公告)日：2015-07-23

申请号：US14547291

申请日：2014-11-19

Applicant: UCB BIOPHARMA SPRL

Inventor： Karen Margrete Miller ,  Marc Roger De Ryck ,  Christian Gilbert J. Wolff ,  Alastair David Griffiths Lawson ,  Helene Margaret Finney ,  Terence Seward Baker

IPC: C07K16/18

CPC classification number: C07K16/18 ,  C07K16/28 ,  C07K2317/34

Abstract: An anti-E1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

Abstract translation: 抗E1离子通道抗体或其结合片段，包含所述抗体的药物组合物，抗体及其组合物的使用，例如用于治疗/调节疼痛以及产生和制备所述抗体的方法。

公开(公告)号：US09988446B2

公开(公告)日：2018-06-05

申请号：US14690892

申请日：2015-04-20

Applicant: UCB Biopharma SPRL

Inventor： Ralph Adams ,  Terence Seward Baker ,  Alastair David Griffiths Lawson

IPC: A61K39/395 ,  C07K16/24

CPC classification number: C07K16/244 ,  C07K2317/33 ,  C07K2317/92

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

公开(公告)号：US20160125124A1

公开(公告)日：2016-05-05

申请号：US14897459

申请日：2014-06-13

Applicant: UCB BIOPHARMA SPRL

Inventor： Jiye Shi ,  Terence Seward Baker ,  Alastair David Griffiths Lawson ,  Xiaofeng Liu

IPC: G06F19/12 ,  C07K16/24

CPC classification number: G16B5/00 ,  C07K16/244 ,  C07K2317/55 ,  C07K2317/76 ,  G16B15/00 ,  G16C20/50 ,  G16C20/90

Abstract: Methods and associated apparatus involving designing a ligand ab initio that will bind to a binding site of a macromolecular target, or of identifying a modification to a ligand for improving the affinity of the ligand to a binding site of a macromolecular target, comprising using information about non-bonding, intra-molecular or inter-molecular atom to atom contacts extracted from a database of biological macromolecules to identify favoured regions adjacent to the binding site for particular atom types and modifying a candidate ligand to increase the intersection between atoms of the candidate ligand and the favoured regions. One or more steps of the methods may be performed by a computer.

Abstract translation: 涉及设计一种将结合大分子靶标的结合位点的配位体或者鉴定对配体的修饰以改善配体对大分子靶标的结合位点的亲和力的方法和相关设备，包括使用关于 从生物大分子数据库中提取的非键合，分子内或分子间或分子间原子与原子接触，以鉴定与特定原子类型的结合位点相邻的有利区域，并修饰候选配体以增加候选配体的原子之间的相交 和优惠地区。 方法的一个或多个步骤可以由计算机执行。

公开(公告)号：US20150118240A1

公开(公告)日：2015-04-30

申请号：US14400812

申请日：2013-05-13

Applicant: UCB Biopharma SPRL

Inventor： Helene Margaret Finney ,  Alastair David Griffiths Lawson ,  Stevan Graham Shaw ,  Bryan John Smith ,  Kerry Louise Tyson ,  Lara Kevorkian ,  Christoph Meier ,  Kaushik Sarkar ,  Paul Alan Atherfold

IPC: C07K16/28 ,  G01N33/50 ,  G01N33/68 ,  A61K47/48 ,  A61K39/395

CPC classification number: C07K16/283 ,  A61K39/3955 ,  A61K47/60 ,  A61K47/643 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/5047 ,  G01N33/564 ,  G01N33/6854 ,  G01N33/6857 ,  G01N33/6893 ,  G01N2333/70535 ,  G01N2500/02 ,  G01N2500/10 ,  G01N2800/104 ,  G01N2800/24 ,  G01N2800/28

Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.

Abstract translation: 本公开涉及对FcRn特异性的抗体，包含其的制剂，治疗中的每一种的使用，用于表达和任选配制所述抗体的方法，编码抗体的DNA和包含所述DNA的宿主。